WT1-Related Wilms Tumor Syndromes Clinical Trials

Find WT1-Related Wilms Tumor Syndromes Clinical Trials Near You

  • Overview
  • Find a Doctor
  • Latest Advances
  • Clinical Trials
  • Treatments
Match to trials
Find the right clinical trials for you in under a minute
Get started

Customize your search results with filters

Phase
    Intervention Type
      Status
        Location:
        Radius:
          Term Search
          You can select from the dropdown list OR enter your own terms to refine the search.

          Last Updated: 01/06/2023

          Need to find the closest trial?
          Sort By Distance
          Save trials for later
          Sign Up
          Not sure about your diagnosis?
          Check Your Symptoms
          Tired of the same old research?
          Check Latest Advances
          Newest Clinical Trials
          4 Clinical Trials
          Sort By

            First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma

            Who is this study for: Patients with Wilms' tumor protein 1-targeted dendritic cell vaccinations for malignant pleural mesothelioma
            Enrollment Status: Recruiting
            Publish Date: November 04, 2022
            Intervention Type: Biological
            Study Drug: Dendritic cell vaccination+Chemotherapy
            Study Phase: Phase 1/Phase 2

            Summary: In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural mesothelioma (MPM). The general objective is to provide the first-in-human experimental demonstration that the combination of platinum/pemetrexed-based chemotherapy with WT1-...

            Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine DSP-7888 for Acute Myeloid Leukemia Patients.

            Who is this study for: Adult patients with Acute Myeloid Leukemia
            Enrollment Status: Recruiting
            Publish Date: March 03, 2021
            Intervention Type: Drug
            Study Drug: DSP-7888 WT1 Peptide Cytotoxic T Lymphocyte Vaccine
            Study Phase: Phase 2

            Summary: This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute myeloid leukemia patients with 1st hematological complete remission (CR). DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

            Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial

            Who is this study for: Adult patients with Acute Myeloid Leukemia
            Enrollment Status: Recruiting
            Publish Date: January 19, 2021
            Intervention Type: Biological
            Study Drug: Autologous WT1 mRNA-Electroporated Dendritic Cell Vaccine
            Study Phase: Phase 2

            Summary: The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell vaccination can significantly prevent relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease.

            Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma

            Who is this study for: Patients with glioblastoma
            Enrollment Status: Recruiting
            Publish Date: January 19, 2021
            Intervention Type: Biological
            Study Drug: Dendritic cell vaccine+Temozolomide chemotherapy
            Study Phase: Phase 1/Phase 2

            Summary: In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation.

            Showing 1-4 of 4

            Last Updated: 01/06/2023

            Better Care. Faster.
            • How MediFind Works
            • Our Story
            • Conditions A-Z
            • Doctor Directory
            • Symptoms Directory
            • Procedures Directory
            • Newsroom
            • Partnering With Us
            • Contact Us
            Subscribe to our newsletter

            Sign up to stay informed about MediFind and get wellness sent your way.

            By subscribing, I agree to MediFind's Terms & Conditions and Privacy Policy.

            • FAQ
            • Feedback
            • Advertising Policy
            • Privacy Policy
            • Terms & Conditions
            Follow Us On
            MediFindBetter Care. Faster.
            © 2023 All Rights Reserved.

            This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.